Q32 Bio Sells Drug Asset to Akebia Therapeutics

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront plus milestone payments up to $592M, extending cash runway to mid-2027 while focusing on alopecia treatment.